Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stent Makers, Interventionists Downplay Impact Of BARI 2D Data

This article was originally published in The Gray Sheet

Executive Summary

There is little debate that BARI 2D trial data unveiled last week affirmed that percutaneous coronary intervention does not extend the lives of patients with type 2 diabetes and stable ischemic heart disease, but stent manufacturers and interventionalists are scratching their heads as to why anybody would be surprised

You may also be interested in...



Comparative Effectiveness Research Alone Is Not Enough, Physicians Say

Comparative effectiveness research will not improve the cost-effectiveness of the health care system if the other factors driving adoption of devices and drugs are not addressed, according to a June 17 editorial in the New England Journal of Medicine

Comparative Effectiveness Research Alone Is Not Enough, Physicians Say

Comparative effectiveness research will not improve the cost-effectiveness of the health care system if the other factors driving adoption of devices and drugs are not addressed, according to a June 17 editorial in the New England Journal of Medicine

American Diabetes Association Meeting In Brief

Diabetes diagnosis: A1C assays, which provide results reflecting average glucose levels over a 2-3 month period, should be the new standard test for making an initial diagnosis of diabetes, an international committee of experts recommended June 5 at the American Diabetes Association annual scientific sessions in New Orleans. A1C is a standard tool for monitoring and managing treatment for diabetes, but diagnosis is typically achieved with a fasting plasma glucose test, or, in some cases, an oral glucose tolerance test. The committee, assembled by ADA, the International Diabetes Federation and the European Association for the Study of Diabetes, noted that A1C values vary less than the other tests and that A1C assays have technical and ease-of-use benefits. An A1C value of 6.5% or greater should generally be used for diagnosis, though it cannot be viewed as an absolute dividing line, the committee said. The three organizations have yet to officially endorse the recommendation. Bio-Rad, MEC Dynamics, Bayer and Roche are among dozens of A1C test kit manufacturers

Related Content

Topics

UsernamePublicRestriction

Register

MT027562

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel